We have two stories to share today from the EORTC-NCI-AACR Molecular Targets conference, which are posted separately owing to different embargo times.
The second posting later focuses exclusively on KRAS and Mirati’s turn in the spotlight.
Due to the embargo, it will not be available until 1545 hrs CET (1045 hrs ET) and will include some thought leader perspectives on the data. I’ll add the link here in due course.
Meanwhile, in the first post (below) we take a keen look at some of the new developmental therapeutics approaches coming through company pipelines.
Which ones shine might brightly and which ones lose their lustre?
As is often the case with early stage trials, translating rational science in preclinical setting doesn’t always translate well into the clinic when humans receive a therapy or particular combination of agents.
To this end, you might be surprised at how much PK/PD issues, half life, dosing/scheduling and other many other factors can severely impact the therapeutic window.
In this post, we look carefully at several targets we have been following preclinically for a while and finally initial clinical is either available or they are heading into the clinic – what can we learn from the presentations?